Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.

Read more

RETA earnings call for the period ending March 31, 2019.

Read more

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.03% and -1.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Read more

This is therefore a comparing of the dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation in Reata Pharmaceuticals Inc. (NASDAQ:RETA) and Synlogic I

Read more

Reata Pharmaceuticals Inc. (NASDAQ:RETA) and Evogene Ltd. (NASDAQ:EVGN), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the divide

Read more

Wall Street analysts forecast that Reata Pharmaceuticals Inc (NASDAQ:RETA) will report earnings per share (EPS) of ($0.97) for the current fiscal quarter, according to Zacks. Four analysts have made e

Read more

Investors often have to make the decision of how aggressive they are going to invest. Some investors looking to make a quick dollar may jump in head first without a plan. This can be dangerous for the

Read more

As Biotechnology businesses, Reata Pharmaceuticals Inc. (NASDAQ:RETA) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), are affected by contrast. This especially applies to their profitability, analyst

Read more

Separating the winners from the losers is a constant challenge for investors. Many focused investors may look to track stock momentum based on historical prices. Reata Pharmaceuticals, Inc. (RETA) cur

Read more

Morning Deals: Monday, Apr. 1
12:00pm, Monday, 01'st Apr 2019
Including deals from Meh, eBay, Macy's, B&H Photo Video, Regal Entertainment Group, Walmart, Rakuten, A4C and more.

Read more

We are contrasting Reata Pharmaceuticals Inc. (NASDAQ:RETA) and Repligen Corporation (NASDAQ:RGEN) on their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings a

Read more

Managing the stock portfolio can be a very challenging task. To manage the portfolio successfully, it can take a lot of dedicated time, effort, and perseverance. Studying the market and being in tune

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank